4D Molecular Therapeutics (FDMT) Non-cash Items (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Non-cash Items data on file, last reported at $5.6 million in Q1 2026.

• Non-cash Items for Q1 2026 came in at $5.6 million, up 12.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (up 12.47% YoY), and the FY2025 annual result was $5.7 million, up 26.16% from the prior year.
• Non-cash Items eased to $5.6 million in Q1 2026 per FDMT's latest filing, from $5.7 million in the prior quarter.
• Over five years, Non-cash Items peaked at $48.0 million in Q4 2022 and troughed at $342000.0 in Q4 2024.
• A 5-year average of $8.8 million and a median of $3.7 million in 2024 frame the typical range for Non-cash Items.
• The sharpest annual moves came in 2024 and 2025: Non-cash Items sank 99.27% in 2024, then jumped 1574.7% in 2025.
• A 5-year view of Non-cash Items shows it stood at $48.0 million in 2022, then declined by 2.47% to $46.9 million in 2023, then slumped by 99.27% to $342000.0 in 2024, then soared by 1574.7% to $5.7 million in 2025, then declined by 2.44% to $5.6 million in 2026.
• Business Quant data shows FDMT's Non-cash Items at $5.6 million in Q1 2026, $5.7 million in Q4 2025, and $6.0 million in Q3 2025.